SynthesisAnnals of internal medicine2024
Hormonal Treatments and Vaginal Moisturizers for Genitourinary Syndrome of Menopause : A Systematic Review.
Synthesis in Annals of internal medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07574216 (The Use of Vaginal Estrogen vs DHEA in Perimenopausal and Menopausal Women), which is not on this map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Use of Vaginal Estrogen vs DHEA in Perimenopausal and Menopausal Women
Who cites it
10 citing papers in PubMed.
- Objective evaluation of the acute effects of pelvic floor muscle training on vaginal dryness in postmenopausal women: a randomized controlled pilot study.Archives of gynecology and obstetrics · 2026Trial
- Awareness of Evidence-Based Treatments Among Women with Dyspareunia: A Cross-Sectional Survey Study.Journal of clinical medicine · 2026Article
- Article
- miR-19b-3p regulates autophagy of BMSCs in hypoxia through PTEN/Akt/mTOR pathway to promote fracture healing.Journal of molecular histology · 2026Article
- Urinary manifestations of genitourinary syndrome of menopause: a review of the pathophysiology, clinical presentation, and management.Gynecology and pelvic medicine · 2026Review
- Sexual dysfunction after cancer: gender differences, tumor-specific patterns, and implications for sexual medicine practice.Oncology reviews · 2026Review
- Genitourinary symptoms and sexual dysfunction in women with premature ovarian insufficiency: a cross-sectional study with age-comparable controls.Frontiers in endocrinology · 2026Article
- Improving the quality of sexual life in postmenopausal women: a qualitative study.BMC public health · 2025Article
- Development and validation of a predictive model for the risk of endocervical curettage positivity.Frontiers in oncology · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPostmenopausal women commonly experience vulvovaginal, urinary, and sexual symptoms associated with genitourinary syndrome of menopause (GSM). PURPOSE: To evaluate effectiveness and harms of vaginal estrogen, nonestrogen hormone therapies, and vaginal moisturizers for treatment of GSM symptoms. DATA SOURCES: Medline, Embase, and CINAHL through 11 December 2023. STUDY SELECTION: Randomized controlled trials (RCTs) of at least 8 weeks' duration enrolling postmenopausal women with at least 1 GSM symptom and reporting effectiveness or harms of hormonal interventions or vaginal moisturizers. DATA EXTRACTION: Risk of bias and data extraction were performed by one reviewer and verified by a second reviewer. Certainty of evidence (COE) was assessed by one reviewer and verified by consensus. DATA SYNTHESIS: From 11 993 citations, 46 RCTs evaluating vaginal estrogen ( LIMITATIONS: Most studies were 12 weeks or less in duration and used heterogeneous GSM diagnostic criteria and outcome measures. Few studies enrolled women with a history of cancer.
conclusionVaginal estrogen, vaginal DHEA, oral ospemifene, and vaginal moisturizers may improve some GSM symptoms in the short term. Few long-term data exist on efficacy, comparative effectiveness, tolerability, and safety of GSM treatments. PRIMARY FUNDING SOURCE: Agency for Healthcare Research and Quality and Patient-Centered Outcomes Research Institute. (PROSPERO: CRD42023400684).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.